title: Hepatitis C virus: the role of molecular mimicry in response to interferon treatment.
abstract: Chronic hepatitis C virus (HCV) infection is one of the major causes of chronic liver disease worldwide. In order for HCV to persist, the virus must escape immune recognition or inhibit the host immune response. The NS5A protein contains the interferon sensitivity-determining region (ISDR) and is able to repress dsRNA-dependent protein kinase (PKR) thus influencing the response to interferon (IFN) therapy. Patients who respond to IFN therapy have stronger antibody reactivity against the NS5A compared to IFN non-responders. Therefore, given the possible role for the ISDR in IFN resistance and differential antibody reactivity, it is possible that variation in ISDR may be involved in viral immune escape and development of persistent HCV infection employing aspects of host mimicry. In this study, pre-treatment samples obtained from HCV infected patients were used to investigate the effect of different NS5A ISDR variants on the IFN antiviral response and their involvement in immune evasion. The NS5A was identified as a homologue of the variable region of immunoglobulins (Ig). The IFN resistant genotypes had higher levels of similarity to Ig compared to IFN sensitive genotypes. Expression of NS5A-6003 (HCV genotype 1b) and NS5A-6074 (HCV genotype 2a) was able to rescue vesicular stomatitis virus (VSV) from IFN inhibition and restore luciferase activity. A correlation between Ig-like NS5A structure and also antibody response with the outcome of IFN treatment was observed.
authors.affiliation: Department of Epidemiology and Surveillance, Canadian Blood Services, Ottawa, Ontario, Canada. samra.uzicanin@blood.ca
authors.forename: Samra
authors.initials: S
authors.lastname: Uzicanin
authors.forename: Yu-Wen
authors.initials: YW
authors.lastname: Hu
authors.forename: Husam
authors.initials: H
authors.lastname: Alsousi
authors.forename: Martin
authors.initials: M
authors.lastname: Pelchat
authors.forename: Lynda
authors.initials: L
authors.lastname: Rocheleau
authors.forename: Rama C
authors.initials: RC
authors.lastname: Nair
authors.forename: Earl G
authors.initials: EG
authors.lastname: Brown
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage*; D002460:Cell Line; D017930:Genes, Reporter; D016174:Hepacivirus / Q000187:drug effects* / Q000276:immunology*; D018937:Hepatitis C Antibodies / Q000097:blood; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D006801:Humans; D057131:Immune Evasion; D007074:Immunoglobulin G / Q000235:genetics; D007372:Interferons / Q000008:administration & dosage* / Q000276:immunology; D008156:Luciferases / Q000032:analysis; D018716:Molecular Mimicry; D017386:Sequence Homology, Amino Acid; D016896:Treatment Outcome; D018116:Vesiculovirus / Q000235:genetics; D017361:Viral Nonstructural Proteins / Q000235:genetics / Q000276:immunology; D010948:Viral Plaque Assay; D012324:RNA-Dependent RNA Polymerase
chemical_list: D000998:Antiviral Agents; D018937:Hepatitis C Antibodies; D007074:Immunoglobulin G; D007372:Interferons; D008156:Luciferases; D017361:Viral Nonstructural Proteins; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase